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to determine the target volume. Episcleral plaques were applied using standard surgical techniques. Plaque repositioning and
veriﬁcation were done using intraoperative ultrasound. The prescribed dose to the apex of the tumor was 85Gy.
Results. Median follow-up was 36 (6–75) months. LC was obtained in 93% (93/100) of cases. 11 out of 100 patients were enucleated,
7 of them due to complications. 2 tumor-related deaths with metastatic disease were observed. 65.5% of patients preserved eye
vision and the remaining 34.5% presented visual impairment. The most acute complication was local haemorrhage in 3 patients
(3%). 38% of late complications included retinopathy in 6 cases, neuropathy in 2, maculopathy in 23, glaucoma neovascular in 5,
vitreous haemorrhage in 2.
Conclusions. The use of plaque radiotherapy allows for safe and effective therapy in patients with choroidal melanoma of various
sizes. The 6-year results are favorable in terms of local control with an acceptable rate of acute and late complications
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Introduction. I-125 brachytherapy is a minimally invasive treatment for low-intermediate risk prostate cancer. Acute urinary
toxicity includes both irritative and obstructive symptoms, which tend to be the bothersome within the ﬁrst few week after
treatment and gradually return to baseline during the next 12 months.
Objective. To evaluate the evolution of urinary morbidity after I-125 prostate brachytherapy using International Prostate Symptom
Score (IPSS).
Methods. Of 41 patients with low and intermediate risk prostate cancer treated with I-125 brachytherapy as monotherapy or com-
bined with EBRT between March of 2011 and December of 2012, 18 had a follow up of 15 months. IPSS was recorded prospectively
within ﬁrst 3 months, then at 9 and 15 months after implant. It was catalogued as mild (≤7), moderate (8–19) or severe (≥20).
Results. From the 18 eligible patients, IPSS preimplantation was mild at 8 of them, and moderate at 10. Within the ﬁrst 3 months,
symptoms were mild, moderate and severe at 12, 5 and 1 patients respectively, at 9 months at 13, 5 and 0 respectively and at
15 months at 11, 6 and 1 respectively. Comparing the baseline and the situation of the last review, 10 patients have improved
and 4 of them were down stanging (passing of moderate to mild symptoms); 5 patients have deteriorated and 3 of them were up
stanging (passing of mild to moderate or severe symptoms); the rest of the patients have not experienced changes bigger than
one point. Only 1 patient within the ﬁrst month postimplant had acute urinary retention and needed RTU. However in the review
at month 15 postimplantation his symptoms were moderate as before implant.
Conclusion. Brachytherapy was generally well tolerated and after 15 months postimplantation most of the patients improved and
had mild symptoms, being complications and severe symptoms unusual.
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Purpose. A rectal cleansing was stated before LDR gynaecological brachytherapy, nowadays some groups advocate it previous to
HDR treatments despite no studies exist analysing the consequences of rectal distension during vaginal cuff brachytherapy. Our
aim of was to deﬁne how rectal distension affects dosimetric values on organs at risk.
Materials and methods. CT sets (337) derived from 92 patients treated with vaginal cuff brachytherapy were re-segmented and re-
planed for studypurpose under the sameparameters. RectumDVHvalueswere extracted andmultiple regressionwas carried out.
Variables analysed were: cylinder angle placement related to the craneo-caudal patient axis, rectum volume, cylinder diameter,
type of rectal content.
Results. Rectum volume had a signiﬁcant association (p< .0001) with the type of rectal content. Gas pockets inside the rectum
produce the highest rectal DVH results. Multiple linear regression model found cylinder angle position, type of rectal content
and cylinder diameter the signiﬁcant variables related to large rectum DVH values analysed.
Conclusion.Our results suggest that amodest improvement on rectal dose deposition could be associatedwith the rectumcleaning
prior to the procedure.
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